Table 1 Diagnostic and treatment characteristics in operative and pathology report cohorts. SD; standard deviation, LN; lymph node
Pathology Reports | Training Cohort (n = 50) | Validation Cohort (n = 50) |
Laterality | ||
 Unilateral | 45 (90%) | 49 (98%) |
 Bilateral | 5 (10%) | 1 (2%) |
Cancer Type | ||
 Invasive | 42 (76.4%) | 41 (80.4%) |
 Non-Invasive | 13 (23.6%) | 10 (19.6%) |
Margins | ||
 Positive | 10 (18.2%) | 9 (17.6%) |
 Negative | 45 (81.8%) | 42 (82.4%) |
Lymph Nodes | ||
 Avg. LNs Examined (SD) | 4.6 (4.3) | 4.3 (3.4) |
 Micro/Macro Metastasis | 16 (29.1%) | 13 (25.5%) |
 Extranodal Extension | 8 (14.5%) | 3 (5.9%) |
Pathologic Diagnosis | ||
 Avg. Number of Foci (SD) | 1.9 (2.0) | 2.0 (2.2) |
 Avg. Nottingham Score (SD) | 6.3 (1.6) | 6.7 (1.6) |
 Avg. Tumour Size in mm. (SD) | 28.2 (28.8) | 27.9 (20.0) |
 Lymphovascular Invasion | 11 (20%) | 10 (19.6%) |
Operative Reports | Training Cohort (n = 50) | Validation Cohort (n = 50) |
Laterality | ||
 Unilateral | 48 (96%) | 49 (98%) |
 Bilateral | 2 (4%) | 1 (2%) |
Procedure Type | ||
 Lumpectomy | 19 (36.5%) | 16 (31.4%) |
 Nipple-Sparing Mastectomy | 15 (28.9%) | 21 (41.2%) |
 Skin-Sparing Mastectomy | 16 (30.7%) | 14 (27.5%) |
 Total Mastectomy | 2 (3.8%) | 0 |
Neoadjuvant Treatment | ||
 Chemotherapy | 4 (7.7%) | 14 (27.5%) |
 None | 48 (92.3%) | 37 (72.5%) |
Immediate Reconstruction | ||
 Mentioned | 50 (96.2%) | 45 (88.2%) |
 Not Mentioned | 2 (3.8%) | 6 (11.8%) |
Axillary Surgery | ||
 Sentinel LN Biopsy | 40 (76.9%) | 38 (74.5%) |
 Axillary LN Dissection | 4 (7.7%) | 5 (9.8%) |
 None | 8 (15.4%) | 8 (15.6%) |